QQQ   304.19 (-0.65%)
AAPL   152.27 (-1.44%)
MSFT   256.74 (-0.62%)
META   186.83 (+0.16%)
GOOGL   102.97 (-1.73%)
AMZN   102.46 (-0.90%)
TSLA   194.63 (+2.45%)
NVDA   211.56 (+0.27%)
NIO   10.82 (-3.31%)
BABA   105.29 (-0.98%)
AMD   83.79 (-2.67%)
T   19.58 (-1.26%)
F   12.98 (-1.89%)
MU   59.97 (-3.91%)
CGC   2.92 (+0.00%)
GE   82.00 (+0.05%)
DIS   108.98 (-1.56%)
AMC   6.32 (+3.95%)
PFE   43.85 (-0.48%)
PYPL   82.87 (-3.10%)
NFLX   364.60 (-0.36%)
QQQ   304.19 (-0.65%)
AAPL   152.27 (-1.44%)
MSFT   256.74 (-0.62%)
META   186.83 (+0.16%)
GOOGL   102.97 (-1.73%)
AMZN   102.46 (-0.90%)
TSLA   194.63 (+2.45%)
NVDA   211.56 (+0.27%)
NIO   10.82 (-3.31%)
BABA   105.29 (-0.98%)
AMD   83.79 (-2.67%)
T   19.58 (-1.26%)
F   12.98 (-1.89%)
MU   59.97 (-3.91%)
CGC   2.92 (+0.00%)
GE   82.00 (+0.05%)
DIS   108.98 (-1.56%)
AMC   6.32 (+3.95%)
PFE   43.85 (-0.48%)
PYPL   82.87 (-3.10%)
NFLX   364.60 (-0.36%)
QQQ   304.19 (-0.65%)
AAPL   152.27 (-1.44%)
MSFT   256.74 (-0.62%)
META   186.83 (+0.16%)
GOOGL   102.97 (-1.73%)
AMZN   102.46 (-0.90%)
TSLA   194.63 (+2.45%)
NVDA   211.56 (+0.27%)
NIO   10.82 (-3.31%)
BABA   105.29 (-0.98%)
AMD   83.79 (-2.67%)
T   19.58 (-1.26%)
F   12.98 (-1.89%)
MU   59.97 (-3.91%)
CGC   2.92 (+0.00%)
GE   82.00 (+0.05%)
DIS   108.98 (-1.56%)
AMC   6.32 (+3.95%)
PFE   43.85 (-0.48%)
PYPL   82.87 (-3.10%)
NFLX   364.60 (-0.36%)
QQQ   304.19 (-0.65%)
AAPL   152.27 (-1.44%)
MSFT   256.74 (-0.62%)
META   186.83 (+0.16%)
GOOGL   102.97 (-1.73%)
AMZN   102.46 (-0.90%)
TSLA   194.63 (+2.45%)
NVDA   211.56 (+0.27%)
NIO   10.82 (-3.31%)
BABA   105.29 (-0.98%)
AMD   83.79 (-2.67%)
T   19.58 (-1.26%)
F   12.98 (-1.89%)
MU   59.97 (-3.91%)
CGC   2.92 (+0.00%)
GE   82.00 (+0.05%)
DIS   108.98 (-1.56%)
AMC   6.32 (+3.95%)
PFE   43.85 (-0.48%)
PYPL   82.87 (-3.10%)
NFLX   364.60 (-0.36%)

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$13.60
-0.45 (-3.20%)
(As of 02/6/2023 01:18 PM ET)
Add
Compare
Today's Range
$13.41
$14.16
50-Day Range
$14.05
$17.95
52-Week Range
$9.84
$18.96
Volume
415,335 shs
Average Volume
530,526 shs
Market Capitalization
$906.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
110.8% Upside
$28.67 Price Target
Short Interest
Healthy
5.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.50mentions of Aclaris Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$460,650 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.39) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

300th out of 1,027 stocks

Pharmaceutical Preparations Industry

142nd out of 500 stocks

ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

ACRS Aclaris Therapeutics, Inc.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Aclaris Therapeutics Provides 2023 Outlook
SVB Securities Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Aclaris Therapeutics Announces Key Leadership Transitions
Aclaris Therapeutics Looks Promising on the Charts
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
11/08/2022
Today
2/06/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$28.67
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+110.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-90,860,000.00
Net Margins
-349.26%
Pretax Margin
-349.26%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.22 per share

Miscellaneous

Free Float
62,215,000
Market Cap
$906.85 million
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Douglas J. Manion
    President, Chief Executive Officer & Director
  • Kevin Balthaser
    Chief Financial Officer
  • Gail Cawkwell
    Chief Medical Officer
  • Joseph B. MonahanJoseph B. Monahan
    Chief Scientific Officer
  • Monica Salamea
    Vice President-Clinical Operations













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

6 analysts have issued 12-month price objectives for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $25.00 to $32.00. On average, they anticipate the company's share price to reach $28.67 in the next twelve months. This suggests a possible upside of 104.0% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 at the start of the year. Since then, ACRS stock has decreased by 10.8% and is now trading at $14.05.
View the best growth stocks for 2023 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,840,000 shares, a decline of 5.0% from the December 31st total of 2,990,000 shares. Based on an average daily volume of 349,100 shares, the short-interest ratio is currently 8.1 days. Currently, 5.5% of the shares of the stock are sold short.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.09. The biotechnology company earned $19.02 million during the quarter, compared to the consensus estimate of $1.61 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative trailing twelve-month return on equity of 39.41%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (0.44%), Allspring Global Investments Holdings LLC (0.10%), Strs Ohio (0.05%), ProShare Advisors LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $14.05.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $936.85 million and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 2/6/2023 by MarketBeat.com Staff